Lymphoma Clinical Trials

Showing 981-1000 of 2,926 trials

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

NCT06573138

A multicenter, prospective trial to evaluate the efficacy and safety of Selinexor, anti-PD-1 antibody plus Golidocitinib in the treatment of relapsed or refractory Natural Killer / T-cell lymphoma.

Lymphoma, Extranodal NK-T-Cell

Ruijin Hospital18 participantsStarted Sep 2024

COMPLETED

Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

NCT01793233

This clinical trial studies blood sample markers of reproductive hormones in assessing ovarian reserve in younger patients with newly diagnosed lymphomas. Studying samples of blood from patients with cancer in the laboratory may help measure the effect of curative therapy for lymphoma on ovarian failure.

Anaplastic Large Cell LymphomaBurkitt LymphomaDiffuse Large B-Cell Lymphoma+2 more

Children's Oncology Group203 participantsStarted Jun 2013

Birmingham, Alabama, United States • Little Rock, Arkansas, United States • Downey, California, United States +104 more locations

Selinexor, Anti-PD-1 Antibody Plus Golidocitinib in R/R NKTCL

Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

Related Searches

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Brentuximab Vedotin or B-CAP in the Treatment of Older Patients With Newly Diagnosed Classical Hodgkin Lymphoma

Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas

Romidepsin Plus Oral 5-Azacitidine in Relapsed/Refractory Lymphoid Malignancies

Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma

Chidamide+Decitabine Plus Anti-PD-1 Antibody for Patients With R/R cHL Who Are Transplant-ineligible or Refused Transplant.

CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Large B-cell Lymphoma

CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma

Cellular Immunotherapy for Relapsed or Refractory Lymphoma Data Collection

Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma

Glucose Intolerance and Diabetes Related to Treatment With Steroids and PEG- Asparaginase in Children and Adolescents With ALL and Lymphoma

A Retrospective Study on Extranodal DLBCL

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

A Study of Chinese Adults With Lymphoma

Characterization and Clinical Impact of the Gut Microbiota in Lymphoma

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

Zanubrutinib, Obinutuzumab and Lenalidomide in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

ACY-1215 for Relapsed/Refractory Lymphoid Malignancies